Get More Information on Precision Oncology Market - Request Sample Report
The Precision Oncology Market Size was valued at USD 100.94 Billion in 2023, and is expected to reach USD 217.61 Billion by 2032, and grow at a CAGR of 9.35%.
The precision oncology market is expected to experience significant growth in the coming years due to the high demand for personalized treatments in the fight against cancer. Personalized medicine not only provides patients with more information to make informed health decisions but also leads to increased patient engagement and a sense of control over their treatment plans. This ultimately contributes to better health outcomes, increased revenue for healthcare providers, and stronger patient-therapist relationships. The Department of Health and Human Services reports that actively engaged patients are more likely to adhere to their treatment plans. The integration of precision oncology with AI, big data analytics, and digital health options is expected to enhance patient outcomes and accelerate drug development.
Nanotechnology and AI have significantly improved the performance of cancer treatment by enabling the development of more precise diagnostic and treatment platforms. For instance, AI-based imaging has enhanced disease characterization on MRIs, leading to more accurate results. Additionally, nanomedicine has demonstrated the potential for revolutionizing cancer treatment through the AI-based design of biological devices known as nanomaterials. The National Institutes of Health (NIH) is focusing on the development of AI-enhanced nanosensors and other biological and nanomaterial devices, including nanoelectronics biosensors.
Key Drivers:
The Increasing Incidence of Cancer Worldwide is Driving the Demand for More Precision Oncology Market.
The Rapid Advancements in Genomic Research and the High Demand for Customized Medicine are Key Drivers of the Precision Oncology Market.
Restraints:
The cost associated with Precision Oncology Treatments is a Significant Restraint on Market Growth.
The Precision Oncology Market Faces Complex Regulatory and Ethical Challenges that can Hinder Its Growth.
Opportunity:
The Integration of Artificial Intelligence (AI) and Big Data Analytics in Precision Oncology Offers Significant Opportunities for Market Expansion.
The Expansion of Precision Oncology into Emerging Markets Presents a Substantial Growth Opportunity.
By Product
The therapeutics segment dominated the market with a 72% revenue share in 2023. This was mainly due to the increasing approval of tumor-agnostic therapies and the unique features of therapeutics targeting specific proteins or mutations driving cancer growth. This market share is expected to continue to grow between 2024 and 2030.
Additionally, the diagnostic tools segment is projected to experience rapid growth, with a 10.6% compound annual growth rate (CAGR) from 2024 to 2032. The diagnostic products available in the precision oncology market will be involved in verification and validation activities, relying on the outcomes from current tests. Moreover, the emergence of technological products for diagnostics has improved decision-making, leading to better clinical outcomes, reduced unnecessary therapies, minimized side effects, and prevention of drug resistance.
Need any customization research on Precision Oncology Market - Enquiry Now
By Cancer Type
By 2023, the breast cancer held the largest market share of 42%. This is subject to the increased focus on breast cancer screening, diagnosis, and surgical and radiation techniques. Furthermore, with expanded research activities, and technology revelations for DNA sequencing, relating to the early detection of breast cancer by patients the overall prognosis presents a growth factor for novel methods of development, especially precision oncology. Moreover, the cervical cancer segment is expected to offer the fastest CAGR of 10.7% over the forecast period. This is because of the growing research projects development in the sector including product launches like the CDC announcing a funding award of USD215 million.
In 2023, North America led the industry accounted for 43% of the market share. The industry in this region is competitive with the presence of most of the major market players including Thermo Fisher Scientific Inc., Invitae Corporation, Illumina, Inc., and Laboratory Corporation of America Holding. Further, a high cancer population, several types of research, the development of a diagnostic software platform, and increased healthcare spending offer new service growth opportunities.
The key market players are Thermo Fisher Scientific Inc., Invitae Corporation, Qiagen N.V., Illumina, Inc., Laboratory Corporation of America Holding, Exact Sciences Corporation, Rain Oncology Inc., Strata Oncology, Inc., Xilis, Inc., Variantyx, Inc., Bioserve, Relay Therapeutics, Acrivon Therapeutics, and other players.
Thermo Fisher Scientific launched the CE-IVD-NGS test in August 2022. The company has also unveiled an analysis software to expand access to precision oncology biomarker testing. The test uses one software interface, and the entire process requires only 20 minutes of hands-on time to obtain results. By simplifying the laboratory process, this may increase the pressure on conducting additional genetic testing in-house and on patients, allowing them to enter the precision oncology context more easily.
In addition, in December 2021, ConcertAI, LLC teamed up with LabCorp to expand precision oncology research. The collaboration is expected to lead to the initiation of clinical trials that may reduce the burden on physician practices, boost patient enrollment and retention, and drive recruitment for clinical trials.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 100.94 Billion |
| Market Size by 2032 | US$ 217.61 Billion |
| CAGR | CAGR of 9.35% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Product Type (Diagnostics, Therapeutics) •By Cancer Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Others) •By End Use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Healthcare Data Companies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific Inc., Invitae Corporation, Qiagen N.V., Illumina, Inc., Laboratory Corporation of America Holding, Exact Sciences Corporation, Rain Oncology Inc., Strata Oncology, Inc., Xilis, Inc., Variantyx, Inc., Bioserve, Relay Therapeutics, Acrivon Therapeutics, and other players |
| Key Drivers | •The Increasing Incidence of Cancer Worldwide is Driving the Demand for More Precision Oncology Market. •The Rapid Advancements in Genomic Research and the Growing Emphasis on Personalized Medicine are Key Drivers of the Precision Oncology Market. |
| RESTRAINTS | •The cost associated with Precision Oncology Treatments is a Significant Restraint on Market Growth. •The Precision Oncology Market Faces Complex Regulatory and Ethical Challenges that can Hinder Its Growth. |
Ans: The North America led Precision Oncology Market.
Ans: The Precision Oncology Market will be valued at USD 217.61 Billion in 2032.
Ans: Therapeutics held the largest share in the Precision Oncology Market in 2023.
Ans: The expected CAGR of the Global Precision Oncology Market during the forecast period is 9.35%
Ans: The Precision Oncology Market was valued at USD 100.94 Billion in 2023.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Precision Oncology Market Segmentation, by Product
7.1 Chapter Overview
7.2 Diagnostics
7.2.1 Diagnostics Market Trends Analysis (2020-2032)
7.2.2 Diagnostics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Therapeutics
7.3.1 Therapeutics Market Trends Analysis (2020-2032)
7.3.2 On-premise Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Precision Oncology Market Segmentation, by Cancer Type
8.1 Chapter Overview
8.2 Breast Cancer
8.2.1 Breast Cancer Market Trends Analysis (2020-2032)
8.2.2 Breast Cancer Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Colorectal Cancer
8.3.1 Colorectal Cancer Market Trends Analysis (2020-2032)
8.3.2 Colorectal Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Cervical Cancer
8.4.1 Cervical Cancer Market Trends Analysis (2020-2032)
8.4.2 Cervical Cancer Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Lung Cancer
8.5.1 Lung Cancer Market Trends Analysis (2020-2032)
8.5.2 Lung Cancer Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Prostate Cancer
8.6.1 Prostate Cancer Market Trends Analysis (2020-2032)
8.6.2 Breast Cancer Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Others
8.3.1 Others Market Trends Analysis (2020-2032)
8.3.2 Prostate Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Precision Oncology Market Segmentation, by End-Use
9.1 Chapter Overview
9.2 Hospitals & Diagnostic Laboratories
9.2. Hospitals & Diagnostic Laboratories Market Trends Analysis (2020-2032)
9.2.2 Hospitals & Diagnostic Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Pharmaceutical & Biotechnology Companies
9.3.1 Pharmaceutical & Biotechnology Companies Market Trends Analysis (2020-2032)
9.3. Pharmaceutical & Biotechnology Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Healthcare Data Companies
9.4.1 Healthcare Data Companies Market Trends Analysis (2020-2032)
9.4.2 Healthcare Data Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.4 North America Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.5 North America Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.6.2 USA Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.6.3 USA Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.7.2 Canada Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.7.3 Canada Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.8.2 Mexico Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.8.3 Mexico Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.6.2 Poland Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.6.3 Poland Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.7.2 Romania Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.7.3 Romania Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.4 Western Europe Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.5 Western Europe Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.6.2 Germany Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.6.3 Germany Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.7.2 France Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.7.3 France Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.8.2 UK Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.8.3 UK Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.9.2 Italy Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.9.3 Italy Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.10.2 Spain Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.10.3 Spain Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.13.2 Austria Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.13.3 Austria Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.4 Asia Pacific Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.5 Asia Pacific Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.6.2 China Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.6.3 China Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.7.2 India Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.7.3 India Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.8.2 Japan Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.8.3 Japan Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.9.2 South Korea Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.9.3 South Korea Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.10.2 Vietnam Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.10.3 Vietnam Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.11.2 Singapore Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.11.3 Singapore Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.12.2 Australia Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.12.3 Australia Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.4 Middle East Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.5 Middle East Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.6.2 UAE Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.6.3 UAE Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.4 Africa Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.5 Africa Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Precision Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.4 Latin America Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.5 Latin America Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.6.2 Brazil Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.6.3 Brazil Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.7.2 Argentina Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.7.3 Argentina Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.8.2 Colombia Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.8.3 Colombia Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Precision Oncology Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Precision Oncology Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Precision Oncology Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
11. Company Profiles
11.1 Thermo Fisher Scientific Inc.,
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Invitae Corporation
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Qiagen N.V.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Illumina, Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Laboratory Corporation of America Holding
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Exact Sciences Corporation
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Rain Oncology Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Strata Oncology, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Xilis, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Variantyx, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Diagnostics
Therapeutics
By Cancer Type
Breast Cancer
Colorectal Cancer
Cervical Cancer
Prostate Cancer
Lung Cancer
Others
By End-Use
Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Healthcare Data Companies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)